CompletedNot Applicable

Notification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NOTIFY-ASCVD)

United States233 participantsStarted 2024-10-22

Plain-language summary

Estimate the impact of notifying both patients and their clinicians of the presence of incidental coronary artery calcium (CAC) on initiation of lipid-lowering therapy in patients with ASCVD who are not receiving lipid-lowering therapy.

Who can participate

Age range18 Years – 84 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Presence of CAC on non-gated chest CT scans performed from 2021 to 2025
✓. Age \<85 years
✓. Diagnosis of ASCVD(coronary artery disease, peripheral artery disease, or cerebrovascular disease)
✓. Visit to Stanford affiliated clinician since 2022 at one of the following Stanford clinics including University affiliated clinics:
✓. Internal Medicine
✓. Family Medicine
✓. Cardiology
✓. Neurology

Exclusion criteria

✕. No diagnosis of ASCVD
✕. Patients receiving lipid-lowering therapy
✕. Dementia
✕. Metastatic cancer or active cancer undergoing chemotherapy
✕. Hospice

What they're measuring

Initiation of lipid-lowering therapy

Timeframe: Month 6

Trial details

NCT IDNCT05858879

SponsorStanford University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03-24

View on ClinicalTrials.gov More ASCVD trials